-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai, September 23, 2021/PRNewswire/ - Hua Medicine (the "Company", Hong Kong Stock Exchange stock code: 2552.
The main purpose of the DREAM study is to evaluate the maintenance of blood sugar and the improvement of pancreatic β-cell function in some patients treated with doxagliptin after the completion of the SEED study without taking hypoglycemic drugs
Continuous improvement to near normal levels after the recent, published by the American Diabetes Association (ADA) a consensus report, the type 2 diabetes medication to stop treatment is defined as "remission (remission)"
Two phase III registered clinical trials completed by Hua Medicine have shown that doxagliptin exhibits long-term stable efficacy and good safety during clinical treatment, effectively improving insulin prime secretion disorders, improving β-cell function and reducing insulin resistance
CBIIC is a high-end dialogue platform between the pharmaceutical industry and the investment community initiated by the China Pharmaceutical Innovation Promotion Association in 2016.
At this CBIIC, in addition to the DREAM research results, Dr.
Highlights of CBIIC of Hua Medicine:
Report name: The world's first diabetes drug under development, Dorzagliatin, diabetes alleviation DREAM research results
Speaker: Ma Jianhua, Director of the Endocrinology Department of Nanjing First Hospital, Member of the Standing Committee of the Diabetes Branch of the Chinese Medical Association
Reporting time: 14:25-14:50, September 25
Report session: the world's first special session of clinical data
Report name: Hua Medicine's future R&D pipeline outlook
Speaker: Chen Li, Founder, CEO and Chief Scientific Officer of Hua Medicine
Reporting time: 9:50-10:15, September 26
Report Session: Listed Company Session
About Dougliptin
Dorzagliatin (dorzagliatin) is the world's first dual-acting glucokinase activator under development, which aims to control the development of progressive degenerative diseases of diabetes by restoring the blood glucose homeostasis of patients with type 2 diabetes
About Hualing
Hua Medicine is a biotechnology company based in China that develops global original and innovative drugs for the unmet clinical needs of patients with diabetes worldwide
